Literature DB >> 28682322

Dyslipidaemia: Anti-PCSK9 vaccines to halt atherosclerosis.

Dario Ummarino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28682322     DOI： 10.1038/nrcardio.2017.106

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.

Authors:  Christine Landlinger; Marianne G Pouwer; Claudia Juno; José W A van der Hoorn; Elsbet J Pieterman; J Wouter Jukema; Guenther Staffler; Hans M G Princen; Gergana Galabova
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983
  1 in total
  3 in total

1.  Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.

Authors:  Domenico Girelli; Fabiana Busti; Giacomo Marchi; Nicola Martinelli; Oliviero Olivieri
Journal:  Intern Emerg Med       Date:  2018-03-01       Impact factor: 3.397

2.  Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis.

Authors:  Fernando Civeira; Estíbaliz Jarauta
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 3.  Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.

Authors:  Peng Kong; Zi-Yang Cui; Xiao-Fu Huang; Dan-Dan Zhang; Rui-Juan Guo; Mei Han
Journal:  Signal Transduct Target Ther       Date:  2022-04-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.